All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
During the EHA2021 Virtual Congress, the GvHD Hub spoke with Eduardo Rodriguez Arboli, University of Seville, Seville, ES. We asked, Are you planning a phase II study of glasdegib in refractory sclerotic chronic GvHD?
Are you planning a phase II study of glasdegib in refractory sclerotic chronic GvHD?
In this video, Arboli reports on the results of a phase I study evaluating the safety and efficacy of glasdegib in patients with sclerotic chronic GvHD. He discusses tolerability, dosing, calcium channel blockers for muscle cramps, and the ongoing phase II study.
Non-myeloablative haploidentical or unrelated cord blood hematopoietic transplant for Hodgkin and non-Hodgkin lymphoma
Giancarlo Fatobene, Vanderson Rocha, and colleagues conducted a retrospective analysis based on patient data obtained from various...
Key communications on GvHD at EHA 2021
During the EHA2021 Virtual Congress, the GvHD Hub spoke with Mohamad Mohty, Hôpital Saint-Antoine, Paris, FR. We asked, What were the key communications on GvHD at EHA 2021?
Subscribe to get the best content related to GvHD delivered to your inbox